oval Sanofi's Meningococcal Conjugate Vaccine secures FDA approval in patients aged two and up By www.pharmafile.com Published On :: Mon, 27 Apr 2020 11:58:57 +0000 Sanofi’s MedQuadfi Meningococcal Conjugate Vaccine has scored FDA approval for the prevention of invasive meningococcal disease, becoming the first and only product available in the US for this indication in patients of at least two years old. Full Article FDA meningococcal disease MenQuadfi pharma Sanofi US Sales and Marketing
oval EU approval for Novartis' Cosentyx in active non-radiographic axial spondyloarthritis By www.pharmafile.com Published On :: Wed, 29 Apr 2020 09:28:04 +0000 Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients. Full Article axial spondyloarthritis Cosentyx EU Novartis pharma Research and Development Sales and Marketing
oval FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 By www.pharmafile.com Published On :: Thu, 07 May 2020 11:35:49 +0000 The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have a mutation that leads to MET exon 14 skipping (METex14), regardless of whether they have previously received any type of treatment. Full Article Incyte Novartis pharma Tabrecta Sales and Marketing
oval FDA approval for Farxiga in new indication in heart failure patients By www.thepharmaletter.com Published On :: Wed, 06 May 2020 14:59:00 +0100 Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and… Full Article AstraZeneca/Cardio-vascular/Diabetes/Farxiga/Focus On/Glucosides/Pharmaceutical/Regulation/SGLT2 inhibitors/UK/US FDA/USA
oval Japan grants ‘exceptional’ approval for remdesivir in COVID-19 By www.thepharmaletter.com Published On :: Fri, 08 May 2020 14:53:00 +0100 As had been widely expected, Gilead Sciences on Thursday announced that the Japanese Ministry of Health,… Full Article Anti-virals/Asia Pacific/Coronavirus/Focus On/Gilead Sciences/Japan/Pharmaceutical/Regulation/Remdesivir/USA/Veklury
oval AbbVie, Allergan score FTC approval for $63B merger with one final hurdle left to go By www.fiercepharma.com Published On :: Tue, 05 May 2020 17:50:19 +0000 AbbVie and Allergan have waited for nearly a year for their much-discussed merger to pass muster. Finally, after pushback from consumer groups and tight scrutiny from regulators, the FTC has granted its green light. The partners face just one final hurdle to consummating their deal. Full Article
oval Justice Department Seeks Removal of Pittsburgh-Area Man Who Served as Nazi Concentration Camp Guard By www.justice.gov Published On :: Fri, 3 Apr 2009 16:10:15 EDT The Department of Justice has initiated removal proceedings against a Sharon, Penn., resident who served as an armed SS guard at two Nazi concentration camps in Germany during World War II. Full Article OPA Press Releases
oval Attorney General Vacates Compean Order, Initiates New Rulemaking to Govern Immigration Removal Proceedings By www.justice.gov Published On :: Wed, 3 Jun 2009 13:06:14 EDT Attorney General Eric Holder today vacated the order issued in Matter of Compean by Attorney General Mukasey in January and announced his intention to initiate a new rulemaking proceeding for regulations to govern claims of ineffective assistance of counsel in removal proceedings. Full Article OPA Press Releases
oval Justice Department Seeks Removal of Detroit-Area Man Who Shot Jews While Serving as Nazi Policeman By www.justice.gov Published On :: Mon, 31 Aug 2009 10:07:31 EDT The Department has initiated removal proceedings against a Troy, Mich., resident based on his participation in violent acts of persecution while serving as an armed member of the Nazi-sponsored Ukrainian Auxiliary Police (UAP) in occupied L’viv, Ukraine, during World War II. Full Article OPA Press Releases
oval Statement of the Attorney General on Senate Judiciary Committee’s Approval of the Fair Sentencing Act By www.justice.gov Published On :: Thu, 11 Mar 2010 16:52:58 EST "I applaud the work of the Senate Judiciary Committee, particularly Chairman Leahy, Ranking Member Sessions and Senators Durbin and Graham, in taking such an important step toward reforming our sentencing laws. I look forward to the Senate and the House approving this legislation quickly so that it can be signed into law." Full Article Speech
oval Federal Government Announces Removal of Obsolete Ships from Suisun Bay By www.justice.gov Published On :: Wed, 31 Mar 2010 16:01:58 EDT The federal government announced today that it would remove the remaining 52 ships that currently sit in the Suisun Bay as part of an agreement with environmental groups that was filed in federal court in Sacramento, Calif. Full Article OPA Press Releases
oval Rochester, New York, Contractor Convicted of Illegal Asbestos Removal and False Statements to OSHA By www.justice.gov Published On :: Mon, 15 Nov 2010 11:56:40 EST A jury in Rochester, N.Y., convicted Keith Gordon-Smith, and his Rochester-based asbestos abatement company, Gordon-Smith Contracting, Inc. (GSCI) of eight counts of knowing violations of the Clean Air Act asbestos work practice standards. Full Article OPA Press Releases
oval Associate Attorney General Tom Perrelli and Interior Secretary Ken Salazar Applaud Final Approval of Cobell Settlement By www.justice.gov Published On :: Mon, 20 Jun 2011 18:47:49 EDT Today, the Departments of Justice and Interior applauded the final approval by U.S. Senior District Judge Thomas F. Hogan of Cobell v. Salazar, a long-running and contentious individual American Indian trust class-action lawsuit. Full Article OPA Press Releases
oval Statements by Attorney General Holder and Agriculture Secretary Vilsack on Court Approval of Pigford II Settlement Agreement By www.justice.gov Published On :: Fri, 28 Oct 2011 12:05:11 EDT “This settlement allows the Department of Agriculture and African-American farmers to focus on the future, and brings us one step closer to giving these farmers a chance to have their claims heard,” said Attorney General Holder. Full Article OPA Press Releases
oval Justice Department Seeks Court Approval of Plan to Provide Comprehensive Services to ELL Students in Denver Public Schools By www.justice.gov Published On :: Mon, 1 Oct 2012 14:27:59 EDT The Department of Justice, the Congress of Hispanic Educators (CHE) and the Denver Public Schools (DPS) have jointly requested court approval of a consent decree that requires that the more than 20,000 English Language Learner (ELL) students enrolled in DPS receive the services they need to overcome language barriers and meaningfully participate in school. The proposed consent decree will benefit all ELLs and LEP parents in the district, including not only the 87 percent of ELL students who are native Spanish speakers, but those who speak one of the 137 other languages spoken in the district as well. Full Article OPA Press Releases
oval FDA approval delayed for Sanofi Genzyme’s next blockbuster By www.bizjournals.com Published On :: Fri, 28 Oct 2016 11:11:53 +0000 Editor's note: This story was originally published Friday morning, and has been updated to reflect the FDA's decision regarding the drug later that day. A U.S. approval decision for a major drug planned to be marketed by Cambridge-based Sanofi Genzyme that had been expected last Friday has been delayed due to “deficiencies” found during a manufacturing site inspection in France. In its third quarter report, released Friday morning, French drugmaker Sanofi (NYSE: SNY) disclosed that “manufacturing… Full Article
oval Sanofi receives FDA approval for quadrivalent meningococcal vaccine By www.biopharma-reporter.com Published On :: Tue, 28 Apr 2020 16:00:00 +0100 The company receives approval for MenQuadfi to prevent meningococcal disease. Full Article Markets & Regulations
oval Impact of COVID-19 on Regulatory Enforcement and Approvals By eyeonfda.com Published On :: Tue, 17 Mar 2020 12:00:24 +0000 The impacts of the COVID-19 pandemic bring change shifts the status quo on a daily basis with both breadth and depth. Everything we as individuals and as a society would normally do is undergoing change. FDA regulatory oversight is one … Continue reading → Full Article Current Affairs FDA Image FDA Policy
oval Impact of COVID-19 on Regulatory Enforcement and Approvals – Part 2 By eyeonfda.com Published On :: Thu, 26 Mar 2020 10:48:35 +0000 Earlier this month I published a blog posting that raised questions related to the potential for disruption of approvals in the wake of FDA actions to limit inspections due to the COVID-19 pandemic. Subsequently I had the opportunity to pose … Continue reading → Full Article Advisory Committee Prepapartion Approval Announcements Current Affairs FDA Policy #coronavirus #COVID-19 #COVID-19 #coronavirus #pharma
oval Impact of COVID-19 on Regulatory Enforcement and Approvals – Part 3 – FDA Adds Resources to Facilitate COVID-19 Research By eyeonfda.com Published On :: Wed, 01 Apr 2020 12:05:05 +0000 With the COVID-19 impact making itself apparent on a daily basis as the numbers climb and organizations respond, the effects on the pharma and biotech sector also shifts. Yesterday FDA announced a new concentration of agency assets to be focused … Continue reading → Full Article Current Affairs FDA Policy
oval Impact of COVID-19 on FDA Enforcement and Approvals – Part 5 – FDA Provides Update to Shape Expectations on New Approvals By eyeonfda.com Published On :: Fri, 17 Apr 2020 15:45:55 +0000 In response to written questions submitted last month regarding the potential for delays, FDA had stated that “CDER remains fully capable to continue daily activities, while responding to the public needs of the current COVID-19 outbreak.” In a subsequent blog … Continue reading → Full Article Approval Announcements COVID19 FDA Policy #coronavirus #COVID19
oval COVID-19 Pandemic Likely to Affect FDA Product Approval Timelines By cohealthcom.org Published On :: Mon, 27 Apr 2020 17:50:36 +0000 April 27, 2020 – As the COVID-19 pandemic continues, the Food and Drug Administration (FDA) must balance safeguarding public health with the desire for timely product reviews. Staff members at the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research are working diligently to keep all of these balls in […] Full Article Regulatory/FDA Biohaven Bristol-Myers Squibb clinical trials COVID-19 drug approvals FDA approval process FDA Approvals
oval EMA starts reviewing Gilead's remdesivir data to accelerate approval of COVID-19 antiviral By www.fiercebiotech.com Published On :: Fri, 01 May 2020 08:07:12 +0000 The European Medicines Agency has begun a rolling review of data on Gilead’s remdesivir, positioning it to cut the time it takes to decide whether to approve the drug in COVID-19 patients. Full Article
oval FDA delays decision on approval of Bristol Myers' CAR-T By www.fiercebiotech.com Published On :: Wed, 06 May 2020 12:02:53 +0000 The FDA has delayed its decision on whether to approve Bristol Myers Squibb’s CAR-T cell therapy by three months. Bristol Myers attributed the delay to its submission of additional information upon the request of the FDA. Full Article
oval MdMYB6 regulates anthocyanin formation in apple both through direct inhibition of the biosynthesis pathway and through substrate removal By feeds.nature.com Published On :: 2020-05-02 Full Article
oval Central catheter removal timing and growth patterns in preterm infants By feeds.nature.com Published On :: 2020-05-05 Full Article
oval It wasn't safe to pit - Kovalainen By en.espnf1.com Published On :: Sun, 26 Sep 2010 16:24:16 GMT While the sight of Heikki Kovalainen grabbing a fire extinguisher and trying to put out a blaze on his Lotus provided one of the more spectacular images of the season, opinion was divided on the wisdom of his actions Full Article
oval Why legislative proposals to improve drug and device development must look beyond FDA approvals By webfeeds.brookings.edu Published On :: Tue, 28 Apr 2015 08:00:00 -0400 Legislative proposals to accelerate and improve the development of innovative drugs and medical devices generally focus on reforming the clinical development and regulatory review processes that occur before a product gets to market. Many of these proposals – such as boosting federal funding for basic science, streamlining the clinical trials process, improving incentives for development in areas of unmet medical need, or creating expedited FDA review pathways for promising treatments – are worthy pursuits and justifiably part of ongoing efforts to strengthen biomedical innovation in the United States, such as the 21st Century Cures initiative in the House and a parallel effort taking shape in the Senate. What has largely been missing from these recent policy discussions, however, is an equal and concerted focus on the role that postmarket evidence can play in creating a more robust and efficient innovation process. Data on medical product safety, efficacy, and associated patient outcomes accrued through routine medical practice and through practical research involving a broad range of medical practices could not only bolster our understanding of how well novel treatments are achieving their intended effects, but reinforce many of the premarket reforms currently under consideration. Below and in a new paper, we highlight the importance of postmarket evidence development and present a number of immediately achievable proposals that could help lay the foundation for future cures. Why is postmarket evidence development important? There are a number of reasons why evidence developed after a medical product’s approval should be considered an integral part of legislative efforts to improve biomedical innovation. First and foremost, learning from clinical experiences with medical products in large patient populations can allow providers to better target and treat individuals, matching the right drug or device to the right patient based on real-world evidence. Such knowledge can in turn support changes in care that lead to better outcomes and thus higher value realized by any given medical product. Similarly, data developed on outcomes, disease progression, and associated genetic and other characteristics that suggest differences in disease course or response to treatment can form the foundation of future breakthrough medical products. As we continue to move toward an era of increasingly-targeted treatments, this important of this type of real-world data cannot be discounted. Finally, organized efforts to improve postmarket evidence development can further establish infrastructure and robust data sources for ensuring the safety and effectiveness of FDA-approved products, protecting patient lives. This is especially important as Congress, the Administration, and others continue to seek novel policies for further expediting the pre-market regulatory review process for high-priority treatments. Without a reliable postmarket evidence development infrastructure in place, attempts to further shorten the time it takes to move a product from clinical development to FDA approval may run up against the barrier of limited capabilities to gather the postmarket data needed to refine a product’s safety and effectiveness profile. While this is particularly important for medical devices – the “life cycle” of a medical device often involves many important revisions in the device itself and in how and by whom it is used after approval – it is also important for breakthrough drugs, which may increasingly be approved based on biomarkers that predict clinical response and in particular subpopulations of patients. What can be done now? The last decade has seen progress in the availability of postmarket data and the production of postmarket evidence. Biomedical researchers, product developers, health care plans, and providers are doing more to collect and analyze clinical and outcomes data. Multiple independent efforts – including the U.S. Food and Drug Administration’s Sentinel Initiative for active postmarket drug safety surveillance, the Patient-Centered Outcomes Research Institute’s PCORnet for clinical effectiveness studies, the Medical Device Epidemiology Network (MDEpiNet) for developing better methods and medical device registries for medical device surveillance and a number of dedicated, product-specific outcomes registries – have demonstrated the powerful effects that rigorous, systematic postmarket data collection can have on our understanding of how medical products perform in the real-world and of the course of underlying diseases that they are designed to treat. These and other postmarket data systems now hold the potential to contribute to data analysis and improved population-based evidence development on a wider scale. Federal support for strengthening the processes and tools through which data on important health outcomes can be leveraged to improve evidence on the safety, effectiveness, and value of care; for creating transparent and timely access to such data; and for building on current evidence development activities will help to make the use of postmarket data more robust, routine, and reliable. Toward that end, we put forward a number of targeted proposals that current legislative efforts should consider as the 2015 policy agenda continues to take shape: Evaluate the potential use of postmarket evidence in regulatory decision-making. The initial Cures discussion draft mandated FDA to establish a process by which pharmaceutical manufacturers could submit real-world evidence to support Agency regulatory decisions. While this is an important part of further establishing methods and mechanisms for harnessing data developed in the postmarket space, the proposed timelines (roughly 12 months to first Guidance for Industry) and wide scope of the program do not allow for a thoughtfully-, collaboratively-considered approach to utilizing real-world evidence. Future proposals should allow FDA to take a longer, multi-stakeholder approach to identify the current sources of real-world data, gaps in such collection activities, standards and methodologies for collection, and priority areas where more work is needed to understand how real-world data could be used. Expand the Sentinel System’s data collection activities to include data on effectiveness. Established by Congress in 2007, Sentinel is a robust surveillance system geared toward monitoring the safety of drugs and biologics. In parallel to the program for evaluating the use of RWE outlined above, FDA could work with stakeholders to identify and pursue targeted extensions of the Sentinel system that begin to pilot collection of such data. Demonstration projects could enable faster and more effective RWE development to characterize treatment utilization patterns, further refine a product’s efficacy profile, or address pressing public health concerns – all by testing strategic linkages to data elements outside of Sentinel’s safety focus. Establish an active postmarket safety surveillance system for medical devices. Congress has already acted once to establish device surveillance, mandating in 2012 that Sentinel be expanded to include safety data on medical devices. To date, however, there has been no additional support for such surveillance or even the capability of individually tracking medical devices in-use. With the recently finalized Unique Device Identifier rule going effect and the ability to perform such tracking on the horizon, the time is now to adopt recent proposals from FDA’s National Medical Device Postmarket Surveillance System Planning Board. With Congressional authorization for FDA to establish an implementation plan and adequate appropriations, the true foundation for such a system could finally be put into place. These next steps are practical, immediately achievable, and key to fully realizing the intended effect of other policy efforts aimed at both improving the biomedical innovation process and strengthening the move to value-based health care. Authors Mark B. McClellanGregory W. DanielMorgan Romine Full Article
oval Biggest Financers of Mountaintop Removal Coal Mining Exposed By www.treehugger.com Published On :: Wed, 06 Apr 2011 09:54:58 -0400 PNC, Citi, and UBS are the top three financial enablers of mountaintop removal coal mining, according to a new report by Rainforest Action Network and the Sierra Club that ranks ten of the world's largest banks.These Full Article Business
oval GMO salmon gets final FDA approval By www.treehugger.com Published On :: Thu, 19 Nov 2015 11:49:50 -0500 The U.S. Food and Drug Administration has approved the first genetically engineered animal for human consumption. Full Article Business
oval Court sides with the bees, overturns EPA approval of a pesticide By www.treehugger.com Published On :: Fri, 11 Sep 2015 12:57:54 -0400 Appeals court calls EPA approval of bee-threatening sulfoxaflor “based on flawed and limited data.” Full Article Business
oval EPA catches Dow in weed-killer lie, asks court to reverse approval By www.treehugger.com Published On :: Mon, 30 Nov 2015 13:01:39 -0500 The agro giant made contradictory claims to the government about the herbicide Enlist Duo, the EPA isn’t happy. Full Article Science
oval EPA surprise: Agency seeks to cancel approval of toxic pesticide By www.treehugger.com Published On :: Wed, 02 Mar 2016 13:22:31 -0500 And the company that makes the chemical, Bayer CropScience, refuses to agree. Full Article Science
oval Even Former Coal Miners Want to End Mountaintop Removal Mining By www.treehugger.com Published On :: Fri, 10 May 2013 14:38:07 -0400 It's time to end this destructive practice, and Appalachian residents descended upon Washington, D.C., this week to demand action. Full Article Energy
oval Biggest dam removal in European history has begun with the Vezins dam By www.treehugger.com Published On :: Mon, 17 Jun 2019 12:46:20 -0400 Removal of the 118-foot-high dam in France will free the Sélune River, bringing wildlife back to the waterway and the bay of Mont-Saint-Michel. Full Article Business
oval Reward fund for information on Jairo Mora Sandoval's murder now $56,000 By www.treehugger.com Published On :: Thu, 13 Jun 2013 10:26:46 -0400 Thank you to all the generous donors! Full Article Science
oval Flexible cooling strip breakthrough for heat removal By www.treehugger.com Published On :: Tue, 26 Sep 2017 08:00:00 -0400 This could keep people from overheating in their wearable electronic outfits or simply in the heat of the ever-warming days Full Article Science
oval Greenpeace Protests Coal & Mountaintop Removal Atop 400 Ft Power Plant By www.treehugger.com Published On :: Mon, 13 Feb 2012 17:25:00 -0500 The green activist group's stunt seeks to draw attention to the devastation wrought by coal. Full Article Energy
oval Quid Pro Quo on Keystone approval? Not likely. By www.treehugger.com Published On :: Thu, 09 May 2013 13:55:55 -0400 As we wait for President Obama and the State Department to make a decision on the proposed Keystone XL pipeline, talk seems to have shifted away from why the pipeline should be rejected to what should be done in the event the project is approved. Full Article Energy
oval World Champion Swimmer Ryan Lochte Puts down the Razor and Picks up the Laser - Ryan Lochte explains the feeling of Gentle Laser Hair Removal By feedproxy.google.com Published On :: 27 Apr 2016 12:55:00 EDT Ryan Lochte explains the feeling of Gentle Laser Hair Removal Full Article Healthcare Hospitals Medical Pharmaceuticals Sports Medical Equipment Broadcast Feed Announcements MultiVu Video
oval Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload - Dr. Elliott Vichinsky on Jadenu By feedproxy.google.com Published On :: 31 Mar 2015 13:15:00 EDT Elliott Vichinsky, MD, University of California, San Francisco (UCSF) Benioff Children's Hospital Oakland Full Article Healthcare Hospitals Medical Pharmaceuticals Pharmaceuticals New Products Services Broadcast Feed Announcements FDA Approval MultiVu Video
oval Boston Scientific Receives FDA Approval For SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System - A Technology Development Story: meet the SYNERGY™ Stent System engineers By feedproxy.google.com Published On :: 05 Oct 2015 11:10:00 EDT A Technology Development Story: meet the SYNERGY™ Stent System engineers Full Article Healthcare Hospitals Medical Pharmaceuticals Pharmaceuticals Broadcast Feed Announcements FDA Approval MultiVu Video
oval World Champion Swimmer Ryan Lochte Puts down the Razor and Picks up the Laser - Ryan Lochte explains the feeling of Gentle Laser Hair Removal By feedproxy.google.com Published On :: 27 Apr 2016 12:55:00 EDT Ryan Lochte explains the feeling of Gentle Laser Hair Removal Full Article Healthcare Hospitals Medical Pharmaceuticals Sports Medical Equipment Broadcast Feed Announcements MultiVu Video
oval Trump contradicts nurse in testy Oval Office exchange over coronavirus protective gear By www.cnbc.com Published On :: Wed, 06 May 2020 22:17:29 GMT President Donald Trump contradicted a nurse who said that access to sufficient supplies of personal protective equipment during the coronavirus pandemic "has been sporadic." Full Article
oval A massive renewable energy scheme in Australia has been recommended for environmental approval By www.cnbc.com Published On :: Mon, 04 May 2020 14:37:56 GMT Several big firms, including Danish wind turbine manufacturer Vestas, are involved in the project. Full Article
oval Moderna's vaccine candidate could potentially get regulatory approval in 2021 By www.cnbc.com Published On :: Thu, 07 May 2020 14:12:03 GMT Moderna has received FDA approval for the company's Covid-19 vaccine to continue into the second phase. CNBC's Meg Tirrell reports. Full Article
oval Pharma giants granted coronavirus approvals but doubts remain on manufacturing a global vaccine By www.cnbc.com Published On :: Mon, 04 May 2020 11:23:14 GMT Experts warn that vaccine timelines look ambitious and argue more thought is needed on manufacturing. Full Article
oval Gottlieb: Covid-19 vaccine may be available for selective use before official approval By www.cnbc.com Published On :: Fri, 08 May 2020 12:09:20 GMT Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, tells "Squawk Box" that a Covid-19 vaccine could be made available for use in "selected circumstances" before it receives official approval for wider distribution. Full Article
oval Walter Sandoval of CD Guadalajara celebrates with Angel Zaldivar after scoring his team's first goal By www.fifa.com Published On :: Tue, 18 Dec 2018 13:48:00 GMT AL AIN, UNITED ARAB EMIRATES - DECEMBER 18: Walter Sandoval of CD Guadalajara celebrates after scoring his team's first goal with Angel Zaldivar of CD Guadalajara during the FIFA Club World Cup UAE 2018 5th Place Match between ES Tunis and CD Guadalajara at Hazza Bin Zayed Stadium on December 18, 2018 in Al Ain, United Arab Emirates. (Photo by David Ramos - FIFA/FIFA via Getty Images) Full Article Area=Tournament Section=Competition Kind=Photo Tournament=FIFA Club World Cup UAE 2018
oval Walter Sandoval of Guadalajara celebrates with Angel Zaldivar after scoring his team's first goal By www.fifa.com Published On :: Tue, 18 Dec 2018 13:48:00 GMT AL AIN, UNITED ARAB EMIRATES - DECEMBER 18: Walter Sandoval of CD Guadalajara celebrates after scoring his team's first goal with Angel Zaldivar of CD Guadalajara during the FIFA Club World Cup UAE 2018 5th Place Match between ES Tunis and CD Guadalajara at Hazza Bin Zayed Stadium on December 18, 2018 in Al Ain, United Arab Emirates. (Photo by Francois Nel/Getty Images) Full Article Area=Tournament Section=Competition Kind=Photo Tournament=FIFA Club World Cup UAE 2018
